885068-75-7

Usage

Uses

Used in Pharmaceutical Research and Development:
Ethyl 2-(3-bromophenyl)-2,2-difluoroacetate is used as a key intermediate in the synthesis of various pharmaceutical drugs and organic compounds. Its reactivity and ability to undergo a wide range of chemical reactions make it a valuable component in the development of new medications and therapies.
Used in Organic Synthesis:
In the field of organic synthesis, Ethyl 2-(3-bromophenyl)-2,2-difluoroacetate serves as a versatile building block for the creation of complex organic molecules. Its unique structure allows it to participate in numerous chemical reactions, facilitating the synthesis of a variety of organic compounds for various applications.
Used in Medicinal Chemistry:
Due to its unique properties and reactivity, Ethyl 2-(3-bromophenyl)-2,2-difluoroacetate is utilized in medicinal chemistry for the exploration of new drug candidates and the development of innovative therapeutic agents. Its potential applications in this field are currently under investigation, with the aim of discovering its full potential in the creation of novel medications.

Upstream product

• 1878-67-7 3-Bromophenylacetic acid 
• 591-18-4 1-Bromo-3-iodobenzene 
• 667-27-6 Ethyl bromodifluoroacetate 
• 14062-30-7 ethyl 2-(3-bromophenyl)acetate 

Downstream Products

• 885068-74-6 (3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-difluoro-acetic acid 
• 915133-40-3 2-(3-bromophenyl)-2,2-difluoroethanol 
• 1231994-84-5 3-{[3-(5-bromopyrimidin-2-yl)phenyl]difluoromethyl}-6-methoxy-1,2,4-triazolo[4,3-b]pyridazine 
• 1201930-32-6 tert-butyl 4-(2-{3-[difluoro-(6-methyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methyl]phenyl}pyrimidin-5-yloxymethyl)piperidine-1-carboxylate 
• 1201930-31-5 2-{3-[difluoro(6-methyl-1,2,4-triazolo-[4,3-b]pyridazin-3-yl)methyl]phenyl}pyrimidin-5-ol 
• 1201930-27-9 [3-(5-bromopyrimidin-2-yl)phenyl]difluoroacetohydrazide 
• 1201930-25-7 [3-(5-bromopyrimidin-2-yl)phenyl]difluoroacetic acid 
• 1201930-21-3 3-{difluoro-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl}-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1201930-20-2 3-[(3-bromophenyl)difluoromethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1201930-00-8 3-(difluoro-{3-[5-(2-morpholin-4-ylethoxy)pyrimidin-2-yl]-phenyl}methyl)-6-methyl-1,2,4-triazolo[4,3-b]pyridazine 
• 1201929-99-8 3-{[3-(5-bromopyrimidin-2-yl)phenyl]difluoromethyl}-6-methyl-1,2,4-triazolo[4,3-b]-pyridazine 
• 1201930-24-6 3-{difluoro-[3-(5-iodopyrimidin-2-yl)phenyl]methyl}-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]-pyridazine 
• 1201929-84-1 3-(difluoro-{3-[5-(2-morpholin-4-ylethoxy)pyrimidin-2-yl]-phenyl}methyl)-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1201929-98-7 3-[difluoro-(3-pyrimidin-2-ylphenyl)methyl]-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 

Relevant academic research and scientific papers

Silver-catalyzed decarboxylative radical allylation of α,α-difluoroarylacetic acids for the construction of CF2-allyl bonds

An efficient silver-catalyzed method of decarboxylative radical allylation of α,α-difluoroarylacetic acids to build CF2-allyl bonds has been developed. Using allylsulfone as an allyl donor, α,α-difluorine substituted arylacetic acids bearing various functional groups are successfully allylated to access a series of 3-(α,α-difluorobenzyl)-1-propylene compounds in moderate to excellent yields in aqueous CH3CN solution under the mild conditions. Experimental studies disclosed that the α-fluorine substitution of arylacetic acid has a great influence on free radical activity and reactivity.

Synthetic method of aromatic ring group or aromatic heterocyclic tetrazole

The synthetic method comprises the following steps: (1) reacting 1.0 eq of ArI or HArI with 1.2 eq of ethyl 2, 2-difluoroacetate in the presence of DMSO as a solvent and 4.0 eq of Cu under the protection of nitrogen at 30 DEG C and 50 DEG C, and purifying to obtain a first intermediate compound; (2) dissolving 1.0 eq of the first intermediate compound in a mixed solvent of THF and water, adding 2.0 eq of LiOH, reacting at room temperature for 2 hours, spin-drying the solvent, adding HCl until the pH value is equal to 3, and filtering to obtain a second intermediate compound; and (3) reacting 1.0 eq of the second intermediate compound with 2.0 eq of diphenyl azide phosphate in the presence of 2.5 eq of triethylamine by taking tert-butyl alcohol as a solvent to generate aromatic ring group or aromatic heterocyclic tetrazole. The invention provides a novel synthetic method of aromatic ring group or aromatic heterocyclic tetrazole, wherein a target compound can be more conveniently obtained, and reagents participating in the reaction are low in toxicity, mild in reaction condition, simple and safe in aftertreatment, good in product quality and suitable for large-scale production.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS

The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF

This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in th

EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF

This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pre

DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR

The present invention provides a compound of formula (I) wherein: R1 is a group selected from -CH2OH, -NHC(O)H and R2 is a hydrogen atom; or R1 together with R2 form the group -NH-C(O)-CH=CH- wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R2; R3 is selected from hydrogen and halogen atoms or groups selected from -SO-R5, -SO2- R5, -NH-CO-NH2, -CO-NH2, hydantoino, C1-4alkyl, C1-4alkoxy and -SO2NR5R6; R4 is selected from hydrogen atoms, halogen atoms and C1-4alkyl groups; R5 is a C1-4alkyl group or C3-8 cycloalkyl; R6 is independently selected from hydrogen atoms and C1-4alkyl groups; n, p and q are independently 0, 1 , 2, 3 or 4; m and s are independently 0, 1 , 2 or 3; r is 0, 1 or 2; with the provisos that: at least one of m and r is not 0; the sum n+m+p+q+r+s is 7, 8, 9, 10, 11 , 12 or 13; the sum q+r+s is 2, 3, 4, 5 or 6 or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).